Arvinas

Yahoo Finance • 5 days ago

Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Elevate Your Investing Strategy: Take advantage of TipR... Full story

Yahoo Finance • 6 days ago

Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded Amazon.com(AMZN)... Full story

Yahoo Finance • 13 days ago

Arvinas announces $100M share repurchase program

* Arvinas (NASDAQ:ARVN [https://seekingalpha.com/symbol/ARVN]) said on Wednesday that its board has authorized and approved [https://seekingalpha.com/filing/10426629] a share repurchase program for the repurchase of up to $100M of the cu... Full story

Yahoo Finance • 13 days ago

Arvinas To Cut Jobs, Out-License Vepdegestrant, And Launch $100 Mln Stock Buyback Plan

(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced plans to jointly select a third party for the out-licensing and commercialization of vepdegestrant. As part of its operational streamlining, Arvinas will reduce its workforce... Full story

Yahoo Finance • 13 days ago

Arvinas, Pfizer to outlicense commercialization of cancer asset vepdegestrant

[Empty licensing agreement application form and pen.] designer491/iStock via Getty Images * Arvinas (NASDAQ:ARVN [https://seekingalpha.com/symbol/ARVN]) and Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) have decided to outlice... Full story

Yahoo Finance • 13 days ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 202... Full story

Yahoo Finance • last month

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participat... Full story

Yahoo Finance • last month

Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco

Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 194.2% during the first quarter, as disclosed in the company’s recent disclosure with t... Full story

Yahoo Finance • 2 months ago

FDA accepts vepdegestrant NDA for ESR1-mutated breast cancer

NEW HAVEN - The U.S. Food and Drug Administration has accepted the New Drug Application for vepdegestrant, an investigational treatment for patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast... Full story

Yahoo Finance • 2 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TAr... Full story

Yahoo Finance • 2 months ago

Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes

Earnings Call Insights: Arvinas, Inc. (ARVN) Q2 2025 MANAGEMENT VIEW * John G. Houston, Chairperson, CEO & President, stated the quarter was eventful with "significant clinical and regulatory programs across our pipeline of PROTAC degr... Full story

Yahoo Finance • 2 months ago

Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates

Arvinas Inc (NASDAQ:ARVN [https://www.chartmill.com/stock/quote/ARVN/profile]) reported its second-quarter 2025 financial results, missing revenue estimates but delivering a narrower-than-expected loss per share. The biopharmaceutical comp... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Shopify (SHOP [https://seekingalpha.com/symbol/SHOP]) * McDonald's Corporation (MCD [https://seeki... Full story

Yahoo Finance • 2 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fin... Full story

Yahoo Finance • 2 months ago

Arvinas, Inc. (ARVN): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish the... Full story

Yahoo Finance • 3 months ago

Arvinas CEO John Houston to retire after successor is named, will remain board chair

Arvinas, Inc. (NASDAQ:ARVN) announced Wednesday that John Houston, Ph.D., Chairperson, President and Chief Executive Officer, has notified the company of his plans to retire from his roles as President and CEO. The announcement comes as th... Full story

Yahoo Finance • 3 months ago

Arvinas CEO John Houston to retire, remain as board chair

NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company with a market capitalization of $585 million, announced Wednesday that John Houston, Ph.D., will retire from his positions as President and Chief Execut... Full story

Yahoo Finance • 3 months ago

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arvinas, Inc. (NASDAQ:ARVN), Semler Scientific Inc. (NASDAQ:SMLR), an... Full story

Yahoo Finance • 4 months ago

Arvinas's SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges

Arvinas, Inc. (NASDAQ:ARVN), a biopharmaceutical company with a market capitalization of $539 million specializing in protein degradation technology, has been making waves in the oncology space with its lead asset, vepdegestrant (vepdeg).... Full story

Yahoo Finance • 4 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In combination with small molecule inhibit... Full story